Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2024

This “Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2024,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chemotherapy Induced Peripheral Neuropathy Understanding

Chemotherapy Induced Peripheral Neuropathy: Overview

Chemotherapy-induced painful neuropathy (CIPN) is a predominantly sensory neuropathy that may be accompanied by motor and autonomic changes. CIPN is a major dose-limiting side effect of several first-line chemotherapeutic agents. The symptoms of CIPN include tingling, pain, decreased sensation, increased sensitivity to touch, temperature, pressure, pain; muscle weakness, and/or irreversible nerve damage. Diagnosis of CIPN is based on history, clinical examination and supporting laboratory investigations. These include electromyography with nerve conduction studies, skin biopsies to evaluate cutaneous nerve innervation, and nerve and muscle biopsies for histopathological evaluation. Treatment of CIPN depends on discontinuation or lowering the dose of the anti-cancer drug. Persistent neuropathic pain can be treated with anti-seizure medications, antidepressants, or analgesics including opiate drugs. Commonly used medications include Lyrica, Neurontin, Cymbalta, Celebrex, Elavil, and Lipoderm Patch. Regular exercise, occupational and physical therapy, reducing alcohol use, and treating preexisting medical conditions (vitamin B12 deficiency) may reduce the risk of CIPN.

Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Peripheral Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Peripheral Neuropathy.

Chemotherapy Induced Peripheral Neuropathy Emerging Drugs Chapters

This segment of the Chemotherapy Induced Peripheral Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chemotherapy Induced Peripheral Neuropathy Emerging Drugs

MN-166 (ibudilast): MediciNovaMN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. MN-166 (ibudilast)'s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies and the molecule is currently under Phase II development for the treatment of chemotherapy induced peripheral neuropathy (CIPN).

ART-123: Asahi Kasei Pharma Corp.ART-123, a recombinant human soluble thrombomodulin composed of the extracellular domain of thrombomodulin. The drug is in Phase II clinical studies for the treatment of chemotherapy induced peripheral neuropathy, and solid tumors. In 2008, ART-123 was approved for the treatment of disseminated intravascular coagulation (DIC) in Japan.

Chemotherapy Induced Peripheral Neuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy Induced Peripheral Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chemotherapy Induced Peripheral Neuropathy

There are approx. 13+ key companies which are developing the therapies for Chemotherapy Induced Peripheral Neuropathy. The companies which have their Chemotherapy Induced Peripheral Neuropathy drug candidates in the most advanced stage, i.e. Phase II include, MediciNova.

Phases

This report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chemotherapy Induced Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chemotherapy Induced Peripheral Neuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Peripheral Neuropathy drugs.

Chemotherapy Induced Peripheral Neuropathy Report Insights

• Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chemotherapy Induced Peripheral Neuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chemotherapy Induced Peripheral Neuropathy drugs?
• How many Chemotherapy Induced Peripheral Neuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Peripheral Neuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Peripheral Neuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chemotherapy Induced Peripheral Neuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MediciNova
• Asahi Kasei Pharma Corp.
• AnnJi Pharmaceutical
• EA Pharma
• Aptinyx
• Sonnet Biotherapeutics Holdings
• Toray
• Solasia Pharma
• Enveric Biosciences
• Regenacy Pharmaceuticals
• NeuroBo Pharmaceuticals

Key Products

• MN-166
• ART-123
• AJ302
• EA-4017
• NYX-2925
• Recombinant Interleukin-6
• TRK-750
• SP-04

Research programme: cannabidiol-combination therapies Enveric Biosciences- Ricolinostat

• NB-01

This product will be delivered within 2 business days.